Skip to main content
. 2022 Sep 29;243(2):186–203. doi: 10.1111/joa.13768

FIGURE 5.

FIGURE 5

Treatment of RP11‐RPE with rapamycin. Rapamycin inhibits the mTOR pathway, and subsequently upregulates the process of autophagy. Increased activation of autophagy enables degradation of misfolded PRPF31 and associated aggregates. This results in an ameliorated phenotype in RP11‐RPE with reduced cytoplasmic aggregates and mutant PRPF31 in the cytoplasm. Improved localisation of wild type PRPF31 is also observed. Figure adapted from Georgiou et al. (2022).